Drug‐Coated Balloon‐Based Versus Drug‐Eluting Stent‐Only Treatment for Large Vessel Coronary Artery Disease

Authors:

Abstract
Background: Drug‐coated balloon (DCB) treatment has shown outcomes comparable to drug‐eluting stent (DES) in small vessel coronary disease. However, evidence for its application in large vessel coronary artery disease (CAD) remains limited. Aims: This study evaluated the clinical impact of DCB‐based percutaneous coronary intervention (PCI) in patients with large vessel CAD. Methods: We retrospectively enrolled 550 consecutive patients with reference vessel diameter ≥ 3.0 mm treated with DCB‐based PCI and propensity‐matched them 1:1 to 550 patients who underwent conventional PCI with second‐generation DES (DES‐only group). The primary endpoint was 2‐year major adverse cardiac events (MACE), defined as a composite of cardiac death, non‐fatal myocardial infarction, definite target lesion thrombosis, and target vessel revascularization (TVR). Results: In the DCB‐based group, 390 patients (70.9%) were treated with DCB alone. Total device length was higher in the DCB group (40.0 ± 23.3 vs. 35.4 ± 23.3 mm; p = 0.001), whereas mean implanted stent length was shorter (9.6 ± 18.4 vs. 35.4 ± 23.3 mm; p < 0.001). The cumulative 2‐year incidence of MACE was significantly lower after DCB‐based PCI than after DES‐only PCI (4.3% vs. 9.7%; hazard ratio: 0.43; 95% confidence interval: 0.26 to 0.70; p = 0.001). TVR was also lower in DCB‐based PCI (3.4% vs. 7.5%; hazard ratio: 0.45; 95% confidence interval: 0.25 to 0.81; p = 0.008). There was no difference in cardiac death, myocardial infarction, or major bleeding. Conclusion: In patients with large vessel CAD, DCB‐based PCI strategy was associated with a significant reduction in MACE compared with DES‐only PCI at 2‐year follow‐up, primarily driven by a lower rate of TVR.

This publication has 35 references indexed in Scilit: